Pancreaticobiliary maljunction predisposes to recurrent pancreatitis, pancreatobiliary stones, and biliary tract tumors. This article aims to enhance clinical recognition to facilitate early diagnosis and standardized management of this condition.
A subscription to JoVE is required to view this content. Sign in or start your free trial.
Method Article
Pancreaticobiliary maljunction predisposes to recurrent pancreatitis, pancreatobiliary stones, and biliary tract tumors. This article aims to enhance clinical recognition to facilitate early diagnosis and standardized management of this condition.
According to extensive case analyses compiled by the Japanese Study Group on Pancreaticobiliary Maljunction (JSPBM), patients with Pancreaticobiliary Maljunction (PBM) exhibit a significantly elevated incidence of biliary tract tumors, ranging from 34% to 39%. This rate is dramatically higher than the population-based incidence of biliary tract tumors in the general population (approximately 0.002%). Beyond malignancy, PBM is associated with multiple common pancreatobiliary disorders, including recurrent pancreatitis, stones within the common pancreatobiliary channel, and pancreatic duct stones, which substantially impair patients' quality of life. Despite its insidious nature and frequent delayed or missed diagnosis, key clinical features such as recurrent pancreatitis, acalculous cholecystitis, and extrahepatic bile duct dilation provide crucial diagnostic clues. Standard diagnostic modalities include abdominal ultrasound, computed tomography (CT), and magnetic resonance cholangiopancreatography (MRCP). Endoscopic retrograde cholangiopancreatography (ERCP) serves as the definitive diagnostic and classification tool. Upon confirmation of diagnosis, patients should undergo curative surgery to mitigate the risk of biliary tract carcinogenesis. This article provides a detailed protocol for the diagnostic and therapeutic approaches to PBM.
Pancreaticobiliary maljunction (PBM) was first reported by Japanese scholars Kozumi K and Kodama T in 1916. However, it was not until 1969 when Babbitt D P proposed an etiological explanation for congenital biliary dilatation and highlighted the correlation between PBM and biliary dilatation that the medical community began to recognize its significance1.
In 1990, the Japanese Study Group on Pancreaticobiliary Maljunction (JSPBM) established diagnostic criteria for PBM, with the defining feature being the union of pancreatic and biliary ducts outside the duodenal wall. JSPBM has maintained an annual registry of PBM c....
Access restricted. Please log in or start a trial to view this content.
This protocol was approved by the Ethics Committee of Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, and written informed consent was obtained from the patient who underwent surgery.
1. Diagnostic methods
Access restricted. Please log in or start a trial to view this content.
The key outcomes in standardized diagnosis and treatment of PBM are as follows:
Definitive diagnosis of suspected cases
Magnetic resonance cholangiopancreatography (MRCP) revealed an anomalous pancreaticobiliary junction, dilated extrahepatic bile ducts, and suspected filling defects in the common bile duct (Figure 1). Endoscopic retrograde cholangiopancreatography (ERCP) was critical for confirmation (Figure 2). .......
Access restricted. Please log in or start a trial to view this content.
Pancreaticobiliary maljunction (PBM) is a congenital anomaly characterized by an abnormal connection between the pancreatic and biliary ducts beyond the duodenal wall, often leading to serious complications such as recurrent pancreatitis and biliary cancer. This study demonstrates a standardized protocol that integrates endoscopic and surgical techniques to enhance diagnostic accuracy and therapeutic safety in the management of PBM.
A critical innovation in our protocol is the preoperative pla.......
Access restricted. Please log in or start a trial to view this content.
The authors have no conflicts of interest to declare.
We are thankful to our colleagues in the operating room. This research was funded by Guangdong Basic and Applied Basic Research Foundation (No. 2024A1515010579, 2023A1515010745, 2023A1515220131), Beijing Xisike Clinical Oncology Research Foundation (Y-MSDPU2022-0826).
....Access restricted. Please log in or start a trial to view this content.
| Name | Company | Catalog Number | Comments |
|---|---|---|---|
| ENDOFLATOR 40 | STORZ | UI400 | |
| ENDOPATH XCEL Trocars | ETHICON | B12LP | |
| ENDOPATH XCEL Trocars | ETHICON | B5LT | |
| HARMONIC 700 with Advanced Hemostasis | ETHICON | HAR736 | |
| HOPKINS Rubina NIR/ICG telescopes | STORZ | 26003BRA | |
| The Autotome RX Cannulating Sphincterotome | Boston Scientific | M00545170 | Autotome RX 44 Cannulating Sphincterotome |
| The Fujifilm ED-580XT Duodenoscope | Fujifilm | ED-580XT | |
| The Jagwire High Performance Guidewire | Boston Scientific | M00556581 | Jagwire Guidewire ST |
| Weck Hem-o-lok Polymer Locking Ligation System | WECK | 544220 Medium | |
| Zimmon Pancreatic Stent | COOK MEDICAL | SPSOF-5-7 |
Access restricted. Please log in or start a trial to view this content.